β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease
- 29 February 2012
- journal article
- Published by Elsevier BV in Molecular Genetics and Metabolism
- Vol. 105 (2), 221-227
- https://doi.org/10.1016/j.ymgme.2011.11.005
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscleMolecular Genetics and Metabolism, 2011
- Transport of Arylsulfatase A across the Blood-Brain Barrier in VitroPublished by Elsevier BV ,2011
- Antibody formation and mannose‐6‐phosphate receptor expression impact the efficacy of muscle‐specific transgene expression in murine Pompe diseaseThe Journal of Gene Medicine, 2010
- New Strategies for Enzyme Replacement Therapy for Lysosomal Storage DiseasesRejuvenation Research, 2010
- IDS Crossing of the Blood-Brain Barrier Corrects CNS Defects in MPSII MiceAmerican Journal of Human Genetics, 2009
- Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe DiseaseMolecular Therapy, 2009
- Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblastsPathoGenetics, 2008
- Biochemical and pharmacological characterization of different recombinant acid α-glucosidase preparations evaluated for the treatment of Pompe diseaseMolecular Genetics and Metabolism, 2008
- Chemically modified β-glucuronidase crosses blood–brain barrier and clears neuronal storage in murine mucopolysaccharidosis VIIProceedings of the National Academy of Sciences of the United States of America, 2008
- Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapyEuropean Journal of Pediatrics, 2007